Protara Therapeutics Inc (TARA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Protara Therapeutics Inc (TARA) has a cash flow conversion efficiency ratio of -0.086x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.95 Million) by net assets ($196.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Protara Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Protara Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TARA total debt and obligations for a breakdown of total debt and financial obligations.
Protara Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protara Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
West Wits Mining Ltd
AU:WWI
|
-0.096x |
|
Omega Flex Inc
NASDAQ:OFLX
|
0.032x |
|
AVE Science & Technology Co Ltd
SHG:688067
|
0.029x |
|
Ring Energy Inc
NYSE MKT:REI
|
0.053x |
|
I-Sheng Electric Wire & Cable Co Ltd
TW:6115
|
-0.011x |
|
Cellectis
PA:ALCLS
|
-0.016x |
|
FVCBankcorp Inc
NASDAQ:FVCB
|
0.030x |
|
Idun Industrier AB Series B
ST:IDUN-B
|
0.091x |
Annual Cash Flow Conversion Efficiency for Protara Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Protara Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Protara Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $196.41 Million | $-56.37 Million | -0.287x | -33.94% |
| 2024-12-31 | $167.13 Million | $-35.81 Million | -0.214x | +61.03% |
| 2023-12-31 | $68.32 Million | $-37.56 Million | -0.550x | -112.10% |
| 2022-12-31 | $102.08 Million | $-26.46 Million | -0.259x | -21.63% |
| 2021-12-31 | $161.91 Million | $-34.50 Million | -0.213x | -81.38% |
| 2020-12-31 | $199.24 Million | $-23.41 Million | -0.117x | +95.20% |
| 2019-12-31 | $6.39 Million | $-15.65 Million | -2.448x | -115.38% |
| 2018-12-31 | $20.44 Million | $-23.23 Million | -1.136x | -76.63% |
| 2017-12-31 | $34.74 Million | $-22.35 Million | -0.643x | -4.42% |
| 2016-12-31 | $38.44 Million | $-23.69 Million | -0.616x | -122.42% |
| 2015-12-31 | $63.41 Million | $-17.57 Million | -0.277x | -128.68% |
| 2014-12-31 | $82.46 Million | $-9.99 Million | -0.121x | -107.43% |
| 2013-12-31 | $-4.11 Million | $-6.70 Million | 1.631x | +171.92% |
| 2012-12-31 | $3.63 Million | $-8.23 Million | -2.268x | -- |
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous cholin… Read more